About Event

Welcome to the 3rd Cell Therapy Analytical Development Summit

The number of cell therapies moving through clinical development continues to soar exponentially in the quest to develop a cure for cancer. This explosive excitement fuels the need to develop analytical tools and technology to effectively characterize cell products to prove their safety, quality, potency, and purity.

Join over 150 industry experts across 3 comprehensive days with 2 dedicated tracks to discuss:

https://cell-therapy-analytics.com/wp-content/uploads/sites/155/2019/08/cropped-cropped-icon-cart-.png

Regulatory guidance into effective potency testing, overcome hurdles from early-stage to late-stage clinical development and shape your strategy in accordance with product availability and regulatory feedback, with expertise shared from Mustang Bio and MD Anderson Cancer Center

https://cell-therapy-analytics.com/wp-content/uploads/sites/155/2019/08/cropped-cropped-icon-cart-.png

Next generation analytical testing for early-stage characterization with genomics and proteomics, as well as advances in phenotyping to analyze purity, identification and quantification, led by Celyad and Vor Biopharma

https://cell-therapy-analytics.com/wp-content/uploads/sites/155/2019/08/cropped-cropped-icon-cart-.png

Validate new tools fit for QC, discussing how to use RNA seq, high throughput data and real time PCR to capture critical quality attributes in a reliable fashion, with leadership shared from Kite Pharma & National Institute of Standards & Technology

https://cell-therapy-analytics.com/wp-content/uploads/sites/155/2019/08/cropped-cropped-icon-cart-.png

Regulatory experience to hit guidelines, reduce delays and standardize across the industry to benchmark accurate results, with expertise shared from BMS, ARM and Gamida Cell

https://cell-therapy-analytics.com/wp-content/uploads/sites/155/2019/08/cropped-cropped-icon-cart-.png

Confidently measure safety in gene engineered, allogeneic products by reviewing assays to characterize efficiency of gene editing and evaluate off-target integration with Century Therapeutics and bluebird bio